The company has expanded its financing deal to $200 million, up from the initial plan of $150 million. The shares are priced at the low end of the projected $9.00 to $9.50 range. The joint bookrunning managers for this offering are JPMorgan, Leerink, and Guggenheim, ensuring a solid backing for this financial move. The stock ticker involved in this offering is COGT.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Cogent Biosciences Inc (COGT, Financial) is $17.00 with a high estimate of $28.00 and a low estimate of $9.00. The average target implies an upside of 73.82% from the current price of $9.78. More detailed estimate data can be found on the Cogent Biosciences Inc (COGT) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Cogent Biosciences Inc's (COGT, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
